Protection Systems Reduce Stroke and Mortality in Carotid Artery Stenting

So far, the main controlled randomized studies have almost exclusively been aimed at comparing the efficacy and safety of carotid artery stenting vs. endarterectomy. Almost all of them have left at operator discretion the choice of the devices to be used during the procedure, which is why there is few direct information to help us make a decision on the cerebral protection system to use, stent material or design, the need for intraprocedural neurophysiological monitoring, and the type of antiplatelet therapy.

Protection Systems Reduce Stroke and Mortality in Carotid Artery Stenting

The aim of this study was to analyze the association between intraprocedural and periprocedural variables and in-hospital stroke and death rates after carotid artery stenting.

 

This trial enrolled a total of 13,086 patients who underwent carotid artery stenting procedures for asymptomatic (63.9%) or symptomatic disease.


Read also: “Estudio SENTINEL: Protección cerebral durante el TAVI”.


The following variables were analyzed: stent design, stent material, neurophysiological monitoring, antiplatelet medication, and use of a cerebral protection system. The primary endpoint was the rate of in-hospital stroke or death.

 

The primary outcome occurred in 2.4% of the population (1.7% in asymptomatic and 3.7% in symptomatic patients).

 

A multivariable analysis showed an independent association between the use of a cerebral protection system and lower in-hospital rates of stroke or death (relative risk [RR]: 0.65; 95% confidence interval [CI]: 0.50 to 0.85), disabling stroke or death (RR: 0.60; 95% CI: 0.43 to 0.84), and stroke (RR: 0.57; 95% CI: 0.43 to 0.77). In the analysis of death rates, no association was found between this event and the use of a cerebral protection system (RR: 0.78; 95% CI: 0.46 to 1.35).


Read also: La endarterectomía precoz parece superior a la angioplastia carotidea en pacientes sintomáticos”.


There was no significant association between stent design, stent material, neurophysiological monitoring, or antiplatelet medication and events such as stroke or death.

 

Conclusion

The use of a cerebral protection system was the only technical variable in carotid artery stenting associated with lower rates of in-hospital stroke and death.

 

Editorial

Retrospective and indirect evidence, plus rationality in the use of cerebral protection systems during carotid artery stenting, resulted in the non-existence of randomized studies testing the usefulness of these devices. We simply adopt them, almost without asking questions. This work with over 13,000 patients is the largest study supporting the idea of always using cerebral protection systems.

 

As regards stent design, this work showed a trend of lower event rates with closed-cell stents, while featuring a wide confidence interval. There is evidence in favor and against both designs. Furthermore, no study has considered parameters such as plaque morphology or vessel anatomy. The most likely scenario is for different patients to benefit from different designs (e.g., open-cell stents for tortuous arteries or closed-cell stents for soft and unstable plaque).

 

Stent material (nitinol or stainless steel) was not associated with events.

 

Antiplatelet medication was not associated with events either, which is both surprising and suspicious. This could be easily explained by the fact that only 2% of patients did not receive antiplatelet medication. Conclusion: Physicians will always indicate dual-antiplatelet therapy.

 

Neurophysiological monitoring showed a trend towards higher rates of stroke and death, but the clear problem here is that the indication was at operator discretion. Neurophysiological monitoring was very probably indicated for those who were suspected of being high-risk patients.

 

Original title: The Use of Embolic Protection Devices Is Associated with a Lower Stroke and Death Rate After Carotid Stenting.

Reference: Christoph Knappich et al. J Am Coll Cardiol Intv 2017;10:1257-65.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....